NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPWGet Free Report) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,200 shares, a decline of 20.0% from the October 31st total of 1,500 shares. Based on an average daily trading volume, of 4,400 shares, the short-interest ratio is currently 0.3 days.

NRx Pharmaceuticals Price Performance

NASDAQ NRXPW opened at $0.05 on Monday. The business has a fifty day simple moving average of $0.06 and a 200 day simple moving average of $0.07. NRx Pharmaceuticals has a 12 month low of $0.04 and a 12 month high of $0.39.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Further Reading

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.